Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies

Seminars in Oncology

Volumn 42, Issue 3, 2015, Pages 429-435

  Eggermont, Alexander M M ^a   Maio, Michele ^b   Robert, Caroline ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; BEVACIZUMAB; CARBOPLATIN; DABRAFENIB; DACARBAZINE; FOTEMUSTINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERLEUKIN 2; IPILIMUMAB; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; SARGRAMOSTIM; TALIMOGENE LAHERPAREPVEC; TICILIMUMAB; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; CANCER VACCINE; IMMUNOLOGIC FACTOR;

ADJUVANT THERAPY; ADVANCED CANCER; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CONTROLLED CLINICAL TRIAL (TOPIC); HIGH RISK PATIENT; HUMAN; MELANOMA; MONOTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; SKIN NEOPLASMS; TUMOR ESCAPE;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MELANOMA; SKIN NEOPLASMS; TUMOR ESCAPE;

EID: 84929145540     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.02.010     Document Type: Review

References (52)

1. A.M. Eggermont, A. Spatz, and C. Robert Cutaneous melanoma Lancet 383 9919 2014 816 827
2. D. Pardoll The blockade of immune checkpoints in immunotherapy Nat Rev Cancer 12 4 2012 252 264
3. A.M. Eggermont, G. Kroemer, and L. Zitvogel Immunotherapy and the concept of a clinical cure Eur J Cancer 49 14 2013 2965 2967
4. C. Robert, J.C. Soria, and A.M. Eggermont Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies Eur J Cancer 49 14 2013 2968 2971
5. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
6. C. Robert, L. Thomas, and I. Bondarenko Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
7. D. Schadendorf, F.S. Hodi, and C. Robert Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma Eur J Cancer 49 2013 abstract 24LBA
8. Maio M, Grob J-J, Aamdal S, et al. Five-year survival rates for treatment-naïve patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015 Feb 23. pii: JCO.2014.56.6018. [Epub ahead of print].
9. K. Margolin, M.S. Ernstoff, and O. Hamid Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial Lancet Oncol 13 2012 459 465
10. J.D. Wolchok, A. Hoos, and S. O'Day Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 2009 7412 7420
11. A. Hoos, A.M.M. Eggermont, and S. Janetzki Improved endpoints for cancer immunotherapy trials J Natl Cancer Inst 102 2010 1388 1397
12. J.S. Weber, K.C. Kaehler, and A. Hauschild Management of immune-related adverse events and kinetics of response with ipilimumab J Clin Oncol 30 2012 2691 2697
13. P. Attia, G.Q. Phan, and A.V. Maker Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 J Clin Oncol 23 2005 6043 6053
14. G.Y. Ku, J. Yuan, and D.B. Page Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival Cancer 116 2010 1767 1775
15. J. Delyon, C. Mateus, and D. Lefevres Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocytes and eosinophils is associated with improved survival Ann Oncol 24 2013 1697 1703
16. C. Ménard, F. Ghiringhelli, and S. Roux CTLA-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res 14 2008 5242 5249
17. D. Hannani, M. Vetizou, and D. Enoti Anticancer immunotherapy by CTLA4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 Cell Res 25 3 2015 399 400
18. J.D. Wolchok, B. Neyns, and G. Linette Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Lancet Oncol 11 2010 155 164
19. A.M. Eggermont, V. Chiarion-Seleni, and J.J. Grob Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial J Clin Oncol 32 Suppl 2014 LBA9008
20. A.M.M. Eggermont, S. Suciu, and R. MacKie Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial Lancet 366 2005 1189 1196
21. A.M.M. Eggermont, S. Suciu, and M. Santinami Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial Lancet 372 2008 117 126
22. A.M. Eggermont, S. Suciu, and A. Testori Long term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma J Clin Oncol 30 2012 3810 3818
23. A.M.M. Eggermont, S. Suciu, and A. Testori Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991 Eur J Cancer 48 2012 218 225
24. A.M. Eggermont, A. Spatz, V. Lazar, and C. Robert Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity? Curr Opin Oncol 24 2012 137 140
25. S. Suciu, N. Ives, and A.M. Eggermont Predictive importance of ulceration on the efficacy of adjuvant interferon-a (IFN): an individual patient data (IPD) meta-analysis of 15 randomized trials in more than 7,500 melanoma patients (pts) J Clin Oncol 32 5s 2014 abstract 9067
26. G. Kroemer, L. Galluzzi, O. Kepp, and L. Zitvogel Immunogenic cell death in cancer therapy Ann Rev Immunol 31 2013 51 72
27. E. Vacchelli, F. Aranda, and A. Eggermont Trial watch: chemotherapy with immunogenic cell death inducers Oncoimmunology 3 2014 e27878
28. L. Galluzzi, L. Senovilla, L. Zitvogel, and G. Kroemer The secretally: immunostimulation by anticancer drugs Nat Rev Drug Discov 11 2012 215 233
29. L. Zitvogel, L. Galluzzi, M.J. Smyth, and G. Kroemer Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance Immunity 39 2013 74 88
30. M.A. Postow, M.K. Callahan, and C.A. Barker Immunologic correlates of the abscopal effect in a patient with melanoma N Engl J Med 366 2012 925 931
31. A.M. Di Giacomo, P.A. Ascierto, and L. Pilla Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial Lancet Oncol 13 9 2012 879 886
32. R. Jamal, K. Belanger, and J.E. Friedmann A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM) J Clin Oncol 32 5s 2014 abstract 9066
33. F.S. Hodi, D. Lawrence, and C. Lezcano Bevacizumab plus ipilimumab in patients with metastatic melanoma Cancer Immunol Res 2 2014 632 642
34. P.A. Prieto, J.C. Yang, and R.M. Sherry CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma Clin Cancer Res 18 2012 2039 2047
35. A.A. Tarhini, J. Cherian, and S.J. Moschos Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma J Clin Oncol 30 3 2012 322 328
36. R.R. Kudchadkar, G.T. Gibney, and D. Dorman A phase IB study of ipilimumab with peginterferon alfa-2b for patients with unresectable stages IIIB/C/IV melanoma J Clin Oncol 32 5s 2014 abstract 9098
37. F.S. Hodi, S. Lee, and D.F. McDermott Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial JAMA 312 2014 1744 1753
38. E. Vacchelli, F. Aranda, and F. Obrist Trial watch: Immunostimulatory cytokines in cancer therapy Oncoimmunology 3 2014 e29030
39. I. Puzanov, M.M. Milhem, and R.H. Andtbacka Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma J Clin Oncol 32 suppl 2014 abstract 9092
40. A. Ribas, F.S. Hodi, M. Callahan, C. Konto, and J. Wolchok Hepatotoxicity with combination of vemurafenib and ipilimumab N Engl J Med 368 2013 1365 1366
41. I. Puzanov, M.L. Callahan, and G.P. Linette Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM) J Clin Oncol 32 suppl 2014 abstract 2511
42. S.L. Topalian, C.G. Drake, and D.M. Pardoll Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity Curr Opin Immunol 24 2012 207 212
43. S.L. Topalian, F.S. Hodi, and J.R. Brahmer Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
44. C. Robert, A. Ribas, and J.D. Wolchok Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Lancet 384 2014 1109 1110
45. J.R. Brahmer, S.S. Tykodi, and L.Q.M. Chow Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
46. O. Hamid, C. Robert, and A. Daud Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 2 2013 134 144
47. S.L. Topalian, M. Sznol, and D.F. McDermott Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab J Clin Oncol 32 2014 1020 1030
48. C. Robert, G.V. Long, and B. Brady Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med 372 4 2015 320 330
49. L. Lorenzo Galluzzi, G. Kroemer, and A. Eggermont Novel immune checkpoint blocker approved for the treatpi ment of advanced melanoma Oncoimmunology 3 2014 e29030
50. J.D. Wolchok, H. Kluger, and M.K. Callahan Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133
51. M. Sznol, H.M. Kluger, and M.K. Callahan Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) J Clin Oncol 2014 32 suppl: LAB9003
52. A.M. Eggermont, and C. Robert Melanoma: smart therapeutic strategies in immuno-oncology Nat Rev Clin Oncol 11 2014 181 182